MetaVia Inc. (NASDAQ: MTVA) shares drop over 10% on Thursday due to profit-taking despite announcing peer-reviewed data supporting its anti-fibrotic MASH drug candidate.

MetaVia Inc. (NASDAQ: MTVA) shares drop over 10% on Thursday due to profit-taking despite announcing peer-reviewed data supporting its anti-fibrotic MASH drug candidate.

Discover why MetaVia Inc. (NASDAQ: MTVA) stock is surging on Friday following new peer-reviewed data on its MASH treatment, reversing Thursday's dip.